Related Experiment Video
Updated: Jan 4, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Potential of Stratified Medicine for High Blood Pressure Management: A Modeling Study Using NHANES Survey Data
Raphaël Porcher1,2,3, Viet-Thi Tran1,2, Jacques Blacher3,4,5
1From the Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Hôtel-Dieu, Center for Clinical Epidemiology, Paris, France (R.P., V.-T.T., P.R.).
Insights
Personalizing intensive hypertension treatment can significantly reduce harms. A stratified medicine approach spares over half of individuals from treatment while minimizing adverse events, offering a more tailored approach to cardiovascular care.
Area of Science:
- Cardiology
- Public Health
- Pharmacogenomics
Background:
- The 2017 ACC/AHA hypertension guidelines lowered treatment thresholds.
- The SPRINT trial indicated patient-specific benefits and harms of intensive treatment.
- Individual patient characteristics influence the risk-benefit profile of antihypertensive therapies.
Purpose of the Study:
- To evaluate the potential benefits of personalizing intensive antihypertensive treatment.
- To compare universal treatment based on 2017 guidelines versus a stratified medicine approach.
- To quantify gains in preventing cardiovascular events and reducing severe adverse events through personalized treatment.
Main Methods:
- Utilized data from the US National Health and Nutrition Examination Survey (2011-2014).
- Applied prediction models from the SPRINT trial to estimate outcomes for individuals aged 50+.
- Compared a universal treatment strategy against a stratified approach excluding patients with unfavorable predicted benefit-risk.
Main Results:
- Under 2017 guidelines, 40.1 million US adults aged 50+ require intensified antihypertensive treatment.
- This universal approach could prevent 795,000 cardiovascular events but cause 848,000 severe adverse events over 5 years.
- A stratified strategy could reduce the number of individuals treated by 52.9% and severe adverse events by 38.3%, with 11.7% fewer cardiovascular events prevented.
Conclusions:
- Personalizing intensive antihypertensive treatment based on predicted benefits and harms can spare over half of individuals from treatment.
- This approach significantly reduces severe adverse events (3x more than benefits prevented).
- Stratified medicine offers a more tailored and safer strategy for managing hypertension in older adults.
Abstract:
The 2017 American College of Cardiology/American Heart Association hypertension guidelines lowered the thresholds for defining and treating hypertension. However, the SPRINT trial showed substantial heterogeneity in benefits and harms of intensive antihypertensive treatment depending on patients' characteristics. We aimed at illustrating the potential gains of personalizing intensive antihypertensive treatment. Using the US National Health and Nutrition Examination Survey 2011 to 2014 (n=2067), and prediction models derived from the SPRINT trial, we computed expected benefits and harms of intensive antihypertensive treatment for individuals aged 50 or more. We compared 2 interventions: (1) intensive antihypertensive treatment for all individuals meeting the 2017 American College of Cardiology/American Heart Association thresholds and (2) a stratified medicine strategy excluding from intensive treatment individuals with predicted unfavorable benefit-risk. Outcome measures were model-predicted 5-year risk of cardiovascular events or death (myocardial infarction, acute coronary, stroke, acute decompensated heart failure, and cardiovascular-related death), and severe adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, and acute kidney injury). Per 2017 American College of Cardiology/American Heart Association guidelines, 40.1 million (39.2%) US individuals aged 50 or more should initiate or intensify antihypertensive treatment, thereby preventing cardiovascular events for 795 000 individuals and inducing severe adverse events for 848 000 over 5 years. A stratified treatment strategy could decrease the number of individuals treated by 21.2 million (52.9%) and reduce the number of individuals with severe adverse events by 38.3%, with 11.7% fewer individuals with cardiovascular events prevented. Personalizing antihypertensive treatment according to predicted benefits and harms could spare treatment for more than half individuals while reducing harms 3× more than benefits.
More Related Videos
07:20Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Factors affecting Blood pressure
Physiological Factors:
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Hypertension I: Introduction
Hypertension and Regulation of Blood Pressure
Errors occurring during blood pressure monitoring
Several factors...